Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-α and IL-6 by peripheral blood cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 47, Issue 2, 1999, Pages 113-118

  Zimecki, Michał ^a   Spiegel, Krystyna ^a   Właszczyk, Andrzej ^b   Kübler, Andrzej ^b   Kruzel, Marian L ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Blood cells; Bovine lactoferin; Interleukin 6; Neutrophil precursors; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 6; LACTOFERRIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CELL; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOREGULATION; MALE; NEUTROPHIL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; ANIMALS; CATTLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-6; LACTOFERRIN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032957111     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. ADAMIK B., ZIMECKI M., WŁASZCZYK A., BEREZOWICZ P. and KÜBLER A. (1998): Lactoferrin effects on the in vitro immune response in critically ill patients. Arch. Immunol. Ther. Exp., 46, 169-176.
2. BELLOMO R. (1992): The cytokine network in the critically ill. Anaesth. Intensive Care, 20, 288-302.
3. BEZAULT J. BHIMANI R., WIPROVNICK J. and FRUMANSKI P. (1994): Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res., 54, 2310-2312.
4. BOXER L. A., BJORKSTEN B., BJORK J., YANG H. H., ALLEN J. M. and BAEHNER R. L. (1992): Neutropenia induced by systemic infusion of lactoferrin. J. Lab. Clin. Med., 9, 866-872.
5. BROCK J. (1995): Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today, 16, 417-419.
6. CHIERICI R. and VIGI V. (1994): Lactoferrin in infant formulae. Acta Paediatr., 402 (suppl.), 83-88.
7. CROUCH S. P. M., SLATER K. J. and FLETCHER J. (1992): Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood, 80, 235-240.
8. DUTHILLE I., MASSON M., SPIK G. and MAZURIER J. (1997): Lactoferrin stimulates the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. Third International Conference of Lactoferrin, May, Le Touquet, France, Program and Abstracts, p. 36.
9. ESPEVIK T. and NISSEN-MAYER J. (1986): A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 25, 99-105.
10. FISHER C. J. JR., AGOSTI J. M., OPAL S. M., LOURY S. F., BALBE R. A., SADOFF I. C., ABRAHAM E., SCHEIN R. M. H. and BENJAMIN E. (1996): Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N. Engl. J. Med., 334, 1697-1702.
11. GERY J. R., DAVIES D., DERR J., KRETT N. and BARRANGER J. A. (1981): Relationship between production and relevance of lymphocyte-activating factor (interleukin 1) by murine macrophages. Cell. Immunol., 64, 293-303.
12. GREENMAN R. L., SCHEIN R. M. H. and MARTIN M. A. (1991): A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. J. Am. Med Assoc., 226, 1097-1102.
13. HANSEN M. B., NIELSEN S. E. and BERG K. (1989): Reexamination and further development of a precise and rapid dye method for measuring cell growth/kill. J. Immunol. Methods, 119, 203-210.
14. HORSFALL A. C., BUTLER D. M., MARINOVA L., WARDEN P. J., WILLIAMS R. O., MARINI R. N. and FELDMANN M. (1997): Suppression of collagen-induced arthritis by continues administration of IL-4. J. Immunol., 159, 5687-5696.
15. HU W. L., MAZURIER J., MONTREUIL J. and SPIK G. (1990): Isolation and partial characterization of a lactoferrin receptor from mouse intestinal brush border. Biochemistry, 29, 535-541.
16. INGLOT A. D., JANUSZ M. and LISOWSKI J. (1996): Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch. Immunol. Ther. Exp., 44, 215-224.
17. MIYAZAWA K., MANTEL C., LU L., MORRISON D. C. and BROXYMEYER H. E. (1991): Lactoferrin-lipopolysaccharide interactions. Effect of lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J. Immunol., 146, 723-729.
18. + peripheral T lymphocytes in patients suffering from juvenile arthritis (JCA) by the extract form calf thymuses. Arch. Immunol. Ther. Exp., 37, 127-132.
19. RICH I. N. (1988): The macrophage as production site for hematopoietic regulator molecules: sensing and responding to normal and pathophysiological signals. Anticancer Res., 8, 1015-1040.
20. ROBERTS A. K., CHIERICI R., ZAWATZKI G., HILL M. J., VOLPATO S. and VIGI V. (1992): Supplementation of an adapted formula with bovine lactoferrin. I. Effect on the infant faecal flora. Acta Paediatr., 81, 119-124.
21. SALO M. (1992): Effect of anaesthesia and surgery on the immune response. Acta Anaesth. Scand., 36, 201-220.
22. SATO R., INANAMI O., TANAKA M. and NAITO Y. (1996): Oral administration of bovine lactoferrin for treatment on intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am. J. Vet. Res., 57, 1443-1446.
23. SZEWCZUK Z., SIEMION I. Z., KUBIK A., WIECZOREK Z., SPIEGEL K., ZIMECKI M., JANUSZ M. and LISOWSKI J. (1989): Proline-rich polypeptide (PRP) fragments and their immunoregulatory properties. In JUNG G. and BAYER E. (eds ): Proceedings of the 20th European Peptide Symposium, September 4-9, 1998, Tübingen, Germany, Walter de Gruyter, Berlin-New York, 741-744.
24. TANAKA T., OMATA Y., SAITO A., SHIMAZAKI K., YAMAUCHI K., TASAKE M., KAWASE K., IGARASHI I. and SUZUKI N. (1995): Toxoplasma gongii: parasiticidal effects of bovine lactoferrin. Exp. Parasitol., 81, 614-617.
25. TERAGUCHI S., OZAWA K., YASUDA S., SHIN K., FUKOWATARI Y. and SHIMAMURA S. (1994): The bacteriostatic effects of orally administered bovine lactoferrin on intestinal Enterobacteriaceae of SPF mice fed bovine milk. Biosci. Biotech. Biochim., 58, 482-487.
26. TRUMPLER U. P. W., STRAUR A. and ROSENMUND A. (1989): Antibacterial prophylaxis with lactoferrin in neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis., 8, 310-318.
27. VAN BERKEL P. H., GEERTS M. E., VAN VEEN H. A., KOORMAN P. M., PIEPER F. R., DE BOER H. A. and NUIJENS J. H. (1995): Glycosylated and unglycosylated human lactoferrin both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibility towards tryptic proteolysis. Biochem. J., 312, 107-114.
28. 2 terminal aminoacid sequence of a T-cell derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. USA, 83, 9679-9683.
29. WAKABAYASHI H., HIRATANI T., UCHIDA K. and YAMAGUCHI H. (1996): Antifungal spectrum and fungicidal mechanism of an N-terminal peptide of bovine lactoferrin. J. Infect. Chemother., 1, 185-189.
30. WŁASZCZYK A., ZIMECKI M., ADAMIK B., DUREK G. and KÜBLER A. (1997): Immunological status of patients subjected to cardiac surgery. Proliferation and production of inflammatory cytokines by peripheral blood leukocytes: regulatory effect of lactoferrin. Arch. Immunol. Ther. Exp., 45, 201-212.
31. YAMAUCHI K., WAKABAYASHI H., HASHIMOTO S., TERAGUCHI S., HAYASAWA H. and TOMITA M. (1998): Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv. Exp. Med. Biol., 443, 261-267.
32. - murine thymocytes. Immunol Lett., 30, 119-124.
33. ZIMECKI M., MAZURIER J. and SPIK G. (1997): Effect of lactoferrin on LFA-1 expression on human peripheral blood mononuclear cells. Third International Conference of Lactoferrin, May, Le Touquet, France, Program and Abstracts, p. 89.
34. ZIMECKI M., MAZURIER J., SPIK G. and KAPP J. A. (1995): Lactoferrin diminishes expression of surface IgM and interleukin 2 receptors on WEHI 231 cells and lowers susceptibility of those cells to anti-IgM induced cell death. Pol. J. Immunol., 20, 324.
35. ZIMECKI M., MAZURIER J., SPIK G. and KAPP A. J. (1995): Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology, 86, 122-127.
36. ZIMECKI M., MAZURIER J., SPIK G. and KAPP J. (1996): Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. Arch. Immunol. Ther. Exp., 44, 51-56.
37. ZIMECKI M., WIECZOREK Z., KAPP J. and PIERCE C. W. (1989): Structures on T cells and macrophages involved in interleukin 1 (IL-1) secretion by macrophages upon contact with syngeneic thymocytes. Arch. Immunol. Ther. Exp., 37, 587-592.
38. ZIMECKI M., WŁASZCZYK A., CHENEAU P., BRUNEL A. S., MAZURIER J., SPIK G. and KÜBLER A. (1998): Immunoregulatory effects of bovine lactoferrin taken orally by healthy individuals. Arch. Immunol. Ther. Exp., 46, 231-240.
39. ZIMECKI M., WŁASZCZYK A., ZAGULSKI T. and KÜBLER A. (1998): Lactoferrin lowers serum interleukin 6 and tumor necrosis factor α levels in mice subjected to surgery. Arch. Immunol. Ther. Exp., 46, 97-104.